Schittecatte M, Charles G, Machowski R, Dumont F, Garcia-Valentin J, Wilmotte J, Papart P, Pitchot W, Wauthy J, Ansseau M
Department of Psychiatry, Hôpital Vincent Van Gogh, Marchienne-Au-Pont, Belgium.
Am J Psychiatry. 1994 Feb;151(2):216-20. doi: 10.1176/ajp.151.2.216.
The authors' goal was to establish, in a large multicenter sample of patients classified according to gender and menopausal status, if the growth hormone (GH) response to clonidine discriminated patients with episodes of major depression from patients with episodes of minor depression.
The GH response to intravenous clonidine administration (150 micrograms) was compared in 71 male and 140 female patients with major depressive episodes and 47 male and 53 female patients with minor depressive episodes. These patients were diagnosed according to Research Diagnostic Criteria.
Differences in the GH response to clonidine between diagnostic groups occurred only between male patients. These results were found in the group as a whole and in each center. The GH responses to clonidine of premenopausal women differed significantly from those of postmenopausal women in each diagnostic group.
These results confirm that gender and menopausal status are of the utmost importance in the interpretation of the clonidine GH test.
作者的目标是，在一个根据性别和绝经状态分类的大型多中心患者样本中，确定生长激素（GH）对可乐定的反应能否区分重度抑郁发作患者和轻度抑郁发作患者。
比较了71名男性和140名女性重度抑郁发作患者以及47名男性和53名女性轻度抑郁发作患者对静脉注射可乐定（150微克）的GH反应。这些患者根据研究诊断标准进行诊断。
诊断组之间对可乐定的GH反应差异仅出现在男性患者中。这一结果在整个组以及每个中心均有发现。在每个诊断组中，绝经前女性对可乐定的GH反应与绝经后女性有显著差异。
这些结果证实，性别和绝经状态在解释可乐定GH试验时至关重要。
